Kyle Mikson
Stock Analyst at Canaccord Genuity
(2.03)
# 3,095
Out of 5,241 analysts
129
Total ratings
37.63%
Success rate
-5.4%
Average return
Main Sectors:
Stocks Rated by Kyle Mikson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Maintains: Hold | $40 → $42 | $38.90 | +7.97% | 4 | May 6, 2026 | |
| WGS GeneDx Holdings | Maintains: Buy | $100 → $75 | $38.85 | +93.05% | 5 | May 5, 2026 | |
| BDSX Biodesix | Maintains: Buy | $20 → $22 | $14.76 | +49.05% | 7 | May 5, 2026 | |
| SEER Seer, Inc. | Initiates: Buy | $4 | $1.75 | +128.57% | 1 | May 4, 2026 | |
| ILMN Illumina | Maintains: Hold | $150 → $140 | $143.24 | -2.26% | 16 | May 1, 2026 | |
| XGN Exagen | Maintains: Buy | $10 → $8 | $3.85 | +107.79% | 7 | Apr 20, 2026 | |
| TXG 10x Genomics | Maintains: Buy | $22 → $32 | $21.52 | +48.70% | 11 | Apr 20, 2026 | |
| RGEN Repligen | Maintains: Hold | $165 → $145 | $103.38 | +40.26% | 5 | Apr 20, 2026 | |
| QTRX Quanterix | Maintains: Hold | $8 → $4 | $2.77 | +44.40% | 9 | Apr 20, 2026 | |
| CSTL Castle Biosciences | Maintains: Buy | $50 → $40 | $18.88 | +111.86% | 7 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $22 | $15.25 | +44.26% | 3 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $1.5 → $1 | $0.93 | +7.19% | 7 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $135 | $98.66 | +36.83% | 11 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105 → $80 | $61.80 | +29.45% | 6 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $80 | $45.48 | +75.90% | 3 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $250 → $285 | $196.91 | +44.74% | 12 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.21 | +147.93% | 8 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.02 | +194.12% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $40 | $2.20 | +1,718.18% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,476 | $6.45 | +22,783.72% | 1 | Mar 30, 2021 |
Veracyte
May 6, 2026
Maintains: Hold
Price Target: $40 → $42
Current: $38.90
Upside: +7.97%
GeneDx Holdings
May 5, 2026
Maintains: Buy
Price Target: $100 → $75
Current: $38.85
Upside: +93.05%
Biodesix
May 5, 2026
Maintains: Buy
Price Target: $20 → $22
Current: $14.76
Upside: +49.05%
Seer, Inc.
May 4, 2026
Initiates: Buy
Price Target: $4
Current: $1.75
Upside: +128.57%
Illumina
May 1, 2026
Maintains: Hold
Price Target: $150 → $140
Current: $143.24
Upside: -2.26%
Exagen
Apr 20, 2026
Maintains: Buy
Price Target: $10 → $8
Current: $3.85
Upside: +107.79%
10x Genomics
Apr 20, 2026
Maintains: Buy
Price Target: $22 → $32
Current: $21.52
Upside: +48.70%
Repligen
Apr 20, 2026
Maintains: Hold
Price Target: $165 → $145
Current: $103.38
Upside: +40.26%
Quanterix
Apr 20, 2026
Maintains: Hold
Price Target: $8 → $4
Current: $2.77
Upside: +44.40%
Castle Biosciences
Apr 20, 2026
Maintains: Buy
Price Target: $50 → $40
Current: $18.88
Upside: +111.86%
Mar 13, 2026
Maintains: Hold
Price Target: $30 → $22
Current: $15.25
Upside: +44.26%
Mar 5, 2026
Maintains: Hold
Price Target: $1.5 → $1
Current: $0.93
Upside: +7.19%
Feb 20, 2026
Maintains: Buy
Price Target: $125 → $135
Current: $98.66
Upside: +36.83%
Feb 20, 2026
Maintains: Buy
Price Target: $105 → $80
Current: $61.80
Upside: +29.45%
Dec 22, 2025
Maintains: Buy
Price Target: $95 → $80
Current: $45.48
Upside: +75.90%
Dec 22, 2025
Maintains: Buy
Price Target: $250 → $285
Current: $196.91
Upside: +44.74%
Apr 10, 2025
Maintains: Buy
Price Target: $3
Current: $1.21
Upside: +147.93%
Nov 14, 2024
Maintains: Buy
Price Target: $3
Current: $1.02
Upside: +194.12%
Aug 16, 2023
Maintains: Overweight
Price Target: $60 → $40
Current: $2.20
Upside: +1,718.18%
Mar 30, 2021
Initiates: Overweight
Price Target: $1,476
Current: $6.45
Upside: +22,783.72%